Therapeutic equivalence of diclofenac sustained-released 75 mg tablets and diclofenac enteric-coated 50 mg tablets in the treatment of painful osteoarthritis

International Journal of Clinical Practice

Volumn 51, Issue 6, 1997, Pages 389-393

  Le Loet X ^a   Dreiser, R L ^b   Le Gros, V ^b   Febvre, N ^b  

^a Rheumatology Service   (France)

^b NOVARTIS PHARMA K K   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPYRETIC ANALGESIC AGENT; DICLOFENAC;

ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COXITIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; ENTERIC COATED TABLET; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED DRUG RELEASE;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DELAYED-ACTION PREPARATIONS; DICLOFENAC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS; PAIN; PATIENT COMPLIANCE; THERAPEUTIC EQUIVALENCY;

EID: 0030815038     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Altman R. International experiences with diclofenac in osteoarthritis. Am J Med 1986; 80(Suppl 4B): 48-52.
2. Ward JR. Efficacy of diclofenac in osteoarthritis: experience in the United States. Am J Med 1986; 80(Suppl 4B): 53-57.
3. Todd PA, Sorkin EM. Diclofenac sodium: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1988; 35: 244-285.
4. Data on file.
5. Chow SC, Liu JP. Recent statistical developments in bioequivalence trials: a review of the FDA guidance. Drug Inform J 1994; 28: 851-864.
6. Westlake WJ. Symmetrical confidence intervals for bioequivalence trials. Biometrics 1976; 32: 741-744.
7. Westlake WJ. Bioequivalence testing - a need to rethink. Biometrics 1981; 37: 589-594.
8. Blackwelder WC. Proving the null hypothesis in clinical trials. Control Clin Trials 1982; 3: 345-353.
9. Schiurmann DJ. Pharmacometrics: a comparison of the two one-sided tests procedure and the power of approach for assessing the equivalence of average bioavailability. J Pharmacokin Biopharm 1987; 15: 657-680.
10. Com-Nougué C, Rodary C. Revue des procédures statistiques pour mettre en évidence l'équivalence de deux traitements. Rev Epidém Santé Publ 1987; 35: 416-430.
11. Mantha S, Thisted R, Foss J et al. A proposal to use confidence intervals for visual analog scale data for pain measurement to determine clinical significance. Anesth Analg 1993; 77: 1041-1047.
12. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996; 313: 36-39.
13. Bakshi R, Ezzet N, Frey L et al. Efficacy and tolerability of diclofenac dispersible in painful osteoarthrosis. Clin Rheumatol 1993; 12: 57-61.
14. Dreiser RL. Etodolac 400LP versus étodolac 200 dans l'arthrose des membres inférieurs. Etude comparative en double aveugle de l'étodolac 400 mg à libération prolongée (1 fois/jour) et de l'étodolac 200 mg (2 fois/jour) après six semaines de traitement dans l'arthrose des membres inférieurs. Rhumatologie 1993; 45: 57-61.
15. ™ 50 mg EC three times daily in the treatment of moderate to severe osteoarthritis of the knee and hip. Curr Ther Res 1990; 48: 476-491.
16. Morgan TO, Nowson C, Murphy J, Snowden R. Compliance and the elderly hypertensive. Drugs 1986; 31(Suppl 4): 174-183.
17. Catalano MA. Worldwide safety experience with diclofenac. Am J Med 1986; 80(Suppl 4B): 81-87.